TikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS |
| August 31, 2022 | August 2022 Bond Updates |
|
VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique... |
| View more at: https://www.prnewswire.com:443/news-releases/tikomeds-ilb-mobilizes-and-modulates-key-growth-factors-that-trigger-a-cascade-of-neuroprotective-mechanisms-able-to-target-all-neuroinflammation-driven-diseases-including-als-301615277.html |
| Related News |